Escient Pharmaceuticals

Escient Pharmaceuticals

  • Founded: 2017
  • Location: San Diego, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Cholestatic pruritus
  • Drug types: DRM, IMM
  • Lead product: EP547
  • Product link:
  • Funding: $120M C Nov 2022; $77.5M B Sep 2020; $40M A May 2018
  • Investors: NEA, Abingworth, Forge Life Science Partners, Avego, PFM Health Sciences, The Eleven Fund, The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), Altitude Life Science Ventures

job board

Short description:

GPCR-targeted Drugs

Drug notes:

Also Clin1 uremic pruritus, Clin0 undisclosed; EP262 Clin1 chronic spontaneous urticaria, Clin1 chronic inducible urticaria, Clin0 atopic dermatitis, Clin0 undisclosed; 2 programs RD undisclosed

Long description:

Escient Pharmaceuticals is developing therapeutics that target G-protein coupled receptors (GPCRs) to treat neurosensory inflammatory disorders. GPCRs are cell surface receptors that make good drug targets being both accessible and causal to many disease pathways. Using state-of-the-art medicinal chemistry and biological tools, Escient is identifying oral therapeutics that can target Mas-related GPCRs (MRGPRs), a class of chemosensory GPCRs expressed on sensory neurons and immune cells that are at the initiation of the neuro-inflammatory disease cascade. Escient’s lead programs targeting MRGPRs, EP262 and EP547, are currently being evaluated for chronic urticaria (hives) and cholestatic pruritus (chronic itchy skin).


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy